Imperative Care’s Zoom Stroke Solution Evaluated in Real-World Studies

August 1, 2023—Imperative Care announced that new data from studies evaluating the company’s Zoom stroke solution were presented at the SNIS 2023, the Society of NeuroInterventional Surgery’s 20th annual meeting held July 31 to August 4 in San Diego, California.

According to the company, Mais Al-Fawaz, MD, from the University of Kentucky in Lexington, Kentucky, presented results from a multicenter study evaluating the association between 0.088-inch guide-catheter positioning and final reperfusion in 428 patients who received an aspiration thrombectomy for ischemic stroke.

The study demonstrated that 0.088-inch intracranial guide-catheter placement in the petrous internal carotid artery (ICA) segment or further distal versus placement in the cervical ICA segment or more proximal was associated with the following:

• A significantly higher first pass effect (43.2% vs 25.5%; P < .001)
• A better rate of thrombolysis in cerebral infarction ≥ 2C reperfusion (71.2% vs 65%; P = .194)
• A significantly shorter median time from groin puncture to final reperfusion (21 vs 35.5 minutes; P < .001)
• A definitively lower total median number of passes (two vs three; P < .015)

“This multicenter analysis further supports the critical importance of intracranial positioning of the guide catheter in achieving a swift recanalization with higher first pass effect and lower procedural time in patients with large vessel occlusion stroke,” commented Shahram Majidi, MD. Dr. Majidi, who is with Mount Sinai in New York, New York, is a lead author of the study.

Jim Milburn, MD, of Ochsner Medical Center in New Orleans, Louisiana, and also a lead author of the study, added, “The Zoom 88 large distal platform (LDP) is the only 0.088-inch guide catheter that can access the intracranial anatomy and get closer to the clot. This has helped me gain even more control over my stroke procedures by allowing me to navigate to the clot more quickly and reduce the risk of clot shearing and distal embolism.”

Imperative Care advised that other presentations at SNIS 2023 included the following:

• Rami Z. Morsi, MD, with University of Chicago Medicine in Chicago, Illinois, presented results from an early single-center experience using the company’s Zoom RDL radial access platform, which was developed specifically for ischemic stroke treatment. The findings showed that Zoom RDL is technically feasible and effective for complex neurointerventional procedures with low complication rates.
• Daryl Goldman, MD, of Mount Sinai presented findings from a three-institution review that suggest that endovascular thrombectomy may be beneficial in patients with distal vessel occlusion (DVO) stroke, with the study concluding that the Zoom aspiration catheters are safe and highly effective in treating DVOs. The results from 78 acute stroke patients with DVOs who were treated with a Zoom aspiration catheter (Zoom 71, Zoom 55, Zoom 45, and Zoom 35) showed that treatment with Zoom aspiration catheters resulted in high rates of reperfusion and fast procedure times, with low rates of symptomatic intracranial hemorrhage.
• A benchtop analysis by Holly Berns, PhD candidate, at Northern Arizona University in Flagstaff, Arizona, that evaluated the effect of intracranial flow parameters on the left side of the brain using various guide catheters for aspiration thrombectomy. The evaluation showed that distal placement of a Zoom 88 can translate to the same or better flow reduction than a balloon guide catheter positioned in the proximal ICA, without the additional time required to set up the balloon.
• Data from a single-center evaluation presented by Sonam Thind, APN, of the University of Chicago Medicine, showed that the Zoom 45 aspiration catheter was technically feasible, safe, and effective for accessing the middle meningeal artery in patients with subdural hematomas.

Imperative Care’s portfolio includes the Zoom 88 LDP and the Zoom RDL platforms. The Zoom stroke solution includes four vessel-matching Zoom aspiration catheters with an angled tip for enhanced clot ingestion, and the Zoom pump with Zoom pod for sterile-field clot capture. All Zoom catheters are designed with the company’s TRX tip which provides 15% greater clot engagement area at the tip of the catheter with smooth tracking through challenging vasculature.

On July 25, the company announced announced FDA 510(k) clearance of its Zoom 88 LDP support, which expands the 0.088-inch intracranial access portfolio for enabling large-bore intracranial access. The company also announced the successful completion of initial cases using Zoom 88 support, which was used during treatment of an acute stroke in a patient with a tandem occlusion that required intracranial access with improved proximal support.